Palliative and supportive care
- Multi-strain probiotic reduces chemotherapy-induced diarrhoea [ESMO 2018 Press Release]
- Regular exercise should be part of cancer care for all patients [ESMO 2018 Press Release]
- Trust in non-conventional therapies by cancer patients not matched with proper awareness about their risks [ESMO 2018 Press Release]
- EMA Recommends Extension of Indications for Epoetin Alfa (Abseamed, Binocrit and Epoetin alfa Hexal)
- EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim
- Management of Cancer Pain in Adult Patients: ESMO Clinical Practice Guidelines
- Diagnosis, Assessment and Management of Constipation in Advanced Cancer: ESMO Clinical Practice Guidelines
- Delirium in Adult Cancer Patients: ESMO Clinical Practice Guidelines
- FDA Approves Avatrombopag for Thrombocytopenia in Adults with Chronic Liver Disease
- Diarrhoea in Adult Cancer Patients: ESMO Clinical Practice Guidelines
- FDA Approves Fulphila to Decrease the Risk of Infection During Cancer Treatment
- ASCO 2018: Alternative Therapies Improve Insomnia Symptoms in Cancer Survivors
- NICE Issues Interventional Procedures Guidance on Low-Level Laser Therapy
- FDA Approves Retacrit as a Biosimilar to Epogen/Procrit
- Withdrawal of Application for a Change to the Marketing Authorisation for Aranesp (Darbepoetin Alfa)
- EMA Recommends Extension of Therapeutic Indications for Fosaprepitant
- EMA Recommends Extension of Therapeutic Indications for Denosumab
- Depression Treatment Does Not Improve the Survival of Depressed Patients with Cancer
- NICE Updates Medical Technologies Guidance on PleurX Peritoneal Catheter Drainage System
- Management of Anaemia and Iron Deficiency in Patients With Cancer: ESMO Clinical Practice Guidelines
- FDA Approves Denosumab for the Prevention of Skeletal-Related Events in Patients with Multiple Myeloma
- ESMO Press Release: ESMO Publishes New Position Paper on Supportive and Palliative Care
- Appetite Stimulants May Provide the Most Rapid Improvement in Cachexia
- Assessment, Grading and Management of Acute Toxicities From CAR-T-Cell Therapy
- Rolapitant i.v. Approved by FDA for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy